Luo Wei, Li Yan, Yang Jiali, Liu Yang, Shi Yue, Luo Hongli
Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
School of Pharmacy, Southwest Medical University, Luzhou, China.
PLoS One. 2025 Jan 31;20(1):e0318463. doi: 10.1371/journal.pone.0318463. eCollection 2025.
With the increasing utilization of anticoagulants, the selection of appropriate anticoagulants has emerged as a significant quandary. The objective of this study was to evaluate recent trend in the utilization and expenditure of anticoagulants within a specific region, aiming to provide valuable insights into the optimal choice of anticoagulants across other healthcare facilities.
The utilization of anticoagulants was retrospectively analyzed. The data on anticoagulant utilizations in tertiary-care hospitals within a district were collected from January 2019 to December 2023. The expenditure, defined daily doses (DDDs), and defined daily cost (DDC) were calculated. The trends in the utilization and expenditure of anticoagulants were examined using linear regression analysis.
From 2019 to 2023, the DDDs of rivaroxaban demonstrated a significant annual increase in most hospitals (p < 0.05). Only a few hospitals exhibited a gradual rise in the consumption of low molecular weight heparin (LMWH) over the same period (p < 0.05). The trend of heparin sodium and warfarin varied across different hospitals. The implementation of the centralized procurement policy, however, resulted in a decline in the consumption of rivaroxaban and LMWH in 2021 and 2022 respectively. The DDC value of rivaroxaban experienced a substantial decrease over the past five years (p = 0.020), declining from 55.20 Chinese Yuan (CNY) in 2019 to 4.28 CNY in 2023. Conversely, there was a slight increase noted in the DDC of heparin sodium during this time frame (p = 0.042).
Over the past five years (2019-2023), there has been an increase in the utilization of rivaroxaban and LMWH. However, their expenditure has decreased. In addition, the utilization and expenditure of warfarin and heparin sodium remained relatively stable. The application prospects of rivaroxaban and LMWH are promising.
随着抗凝剂使用的增加，选择合适的抗凝剂已成为一个重大难题。本研究的目的是评估特定区域内抗凝剂使用和支出的近期趋势，旨在为其他医疗机构抗凝剂的最佳选择提供有价值的见解。
对抗凝剂的使用情况进行回顾性分析。收集了2019年1月至2023年12月期间某地区三级医院抗凝剂使用的数据。计算了支出、限定日剂量（DDD）和限定日费用（DDC）。使用线性回归分析检查抗凝剂使用和支出的趋势。
2019年至2023年期间，大多数医院利伐沙班的DDD呈显著年度增长（p < 0.05）。同期只有少数医院低分子量肝素（LMWH）的消耗量呈逐渐上升趋势（p < 0.05）。肝素钠和华法林的趋势在不同医院有所不同。然而，集中采购政策的实施分别导致2021年和2022年利伐沙班和LMWH的消耗量下降。利伐沙班的DDC值在过去五年中大幅下降（p = 0.020），从2019年的55.20元人民币降至2023年的4.28元人民币。相反，在此期间肝素钠的DDC略有增加（p = 0.042）。
在过去五年（2019 - 2023年）中，利伐沙班和LMWH的使用有所增加。然而它们的支出却有所下降。此外，华法林和肝素钠的使用和支出保持相对稳定。利伐沙班和LMWH的应用前景广阔。
